Improving Resection Rates Among African Americans With NSCLC
Non-small Cell Lung Cancer (NSCLC)
About this trial
This is an interventional health services research trial for Non-small Cell Lung Cancer (NSCLC) focused on measuring non-small cell lung cancer (NSCLC)
Eligibility Criteria
Inclusion Criteria:
- AA race
- Clinically suspicious or biopsy-proven, early stage NSCLC, and
- Ages 21 years and older
Exclusion Criteria:
- Previous history of lung cancer
- Spread of newly diagnosed probably/proven lung cancer to other part of the body
- Diagnosis of synchronous cancer other than non-melanoma skin cancer or lung cancer, and
- Receipt of surgical resection or radiosurgery for lung cancer since diagnosis with probable/proven lung cancer
Sites / Locations
- Beebe Healthcare Tunnell Cancer Center
- Saint Joseph's/Candler Hospital
- Stroger Hospital of Cook County
- Ochsner NCORP
- Beaumont Hospital - Royal Oak
- Metro-Minnesota NCORP
- Nevada Cancer Research Foundation
- Wake Forest University Health Sciences
- Fox Chase
- Virginia Commonwealth University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Usual Care Arm
Intervention Arm
Participants who are assigned to the usual care arm may receive the following services: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
The PN will provide each patient with a copy of the NCI's "What You Need to Know About Lung Cancer" booklet and encourage them to re-contact his/her primary care physician (or the physician who diagnosed their probable/proven NSCLC) to discuss treatment options. The PNs will provide patients with their contact information and brief patients on their role. The PNs will navigate study participants for up to 4 months (16 weeks, 112 days) after NSCLC diagnosis, until the patient is deemed ineligible for LDTCI (i.e., lung resection or SBRT) by their physician(s), until receipt of LDTCI, or death (whichever comes first). During the EPDPN intervention period, PNs will contact each intervention group participant by telephone (or in-person) on weekly basis (at minimum).